Targeting the gastrointestinal tract to develop novel therapies for HIV

Clin Pharmacol Ther. 2015 Oct;98(4):381-6. doi: 10.1002/cpt.186. Epub 2015 Aug 21.

Abstract

Despite the use of antiretroviral therapy (ART), which delays and/or prevents AIDS pathogenesis, human immunodeficiency virus (HIV)-infected individuals continue to face increased morbidities and mortality rates compared with uninfected individuals. Gastrointestinal (GI) mucosal dysfunction is a key feature of HIV infection, and is associated with mortality. In this study, we review current knowledge about mucosal dysfunction in HIV infection, and describe potential avenues for therapeutic targets to enhance mucosal function and decrease morbidities and mortalities in HIV-infected individuals.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-HIV Agents / therapeutic use*
  • Drug Design*
  • Gastrointestinal Tract / drug effects*
  • Gastrointestinal Tract / immunology
  • Gastrointestinal Tract / virology
  • HIV / drug effects*
  • HIV / immunology
  • HIV / pathogenicity
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • Humans
  • Immunity, Mucosal / drug effects*
  • Molecular Targeted Therapy
  • Mucous Membrane / drug effects
  • Mucous Membrane / immunology
  • Mucous Membrane / virology

Substances

  • Anti-HIV Agents